GLP-1 Receptor Agonists: Clinical Research Guide
GLP-1 receptor agonists represent the most significant class in metabolic research. This page provides technical specifications, mechanism summaries, and clinical trial data for GLP-1 compounds available from QSC.
Order GLP-1 Compounds from QSC
Semaglutide, Tirzepatide, Retatrutide. ≥99% HPLC. Janoshik COA. 8-region domestic shipping.
Order at QSC →Compound Specifications
| Compound | CAS | MW (Da) | Receptor(s) | Half-life | Route | Trial Wt Loss* |
|---|---|---|---|---|---|---|
| Semaglutide | 910463-68-2 | 4113.58 | GLP-1 | ~168h | SC | 15–17% |
| Tirzepatide | 2023788-19-2 | 4813.48 | GLP-1 + GIP | ~120h | SC | 20–22% |
| Retatrutide | 2381089-83-2 | ~5000 | GLP-1 + GIP + GCG | ~90h | SC | 24–26% |
| Survodutide | 2472836-24-9 | ~4800 | GLP-1 + Glucagon | ~168h | SC | ~18% |
| Liraglutide | 204656-20-2 | 3751.20 | GLP-1 | ~13h | SC | ~8% |
| Orforglipron | 2411514-39-9 | 527.6 | GLP-1 (non-peptide) | ~12h | Oral | ~15% |
*Phase 2/3 clinical trial data. Not predictive of individual research outcomes.
Semaglutide (CAS 910463-68-2)
C18 fatty diacid-conjugated GLP-1 analogue with Aib at position 8 (DPP-4 resistance). ~7-day half-life via albumin binding. STEP-1 trial: 14.9% mean weight reduction at 68 weeks.
Tirzepatide (CAS 2023788-19-2)
First dual GLP-1/GIP receptor agonist. GIP receptor activation improves adipocyte insulin sensitivity and reduces nausea vs pure GLP-1 agonism. SURMOUNT-1: 22.5% mean weight reduction at highest dose.
Retatrutide (CAS 2381089-83-2)
Triple GLP-1/GIP/glucagon receptor agonist. Glucagon component activates brown adipose tissue thermogenesis, increasing energy expenditure. Phase 2 NEJM data: 24.2% mean weight reduction at 48 weeks.
Research Use Only. All compounds are for laboratory research only. Not for clinical prescription or human administration.